Thursday , 19 October 2017
Breaking News
Home » Research & Innovation » University of Virginia wins NIH backing for peripheral arterial disease research

University of Virginia wins NIH backing for peripheral arterial disease research

University of Virginia Health_System

University of Virginia Health System

A team of researchers at the University of Virginia School of Medicine will examine whether peripheral arterial disease, a common circulation problem, can be treated with an existing drug compound developed for another purpose.
The work is being funded by the National Institutes of Health, which announced the award June 18. University of Virginia is one of nine academic research groups that will share $12.7 million in NIH funding.

“We are delighted to receive this highly competitive award,” said Dr. Brian H. Annex, division chief of cardiovascular medicine at U.Va. and the principal investigator for the grant. “We have the opportunity to rapidly determine the ability of this investigational agent to improve the primary problem of reduced blood flow to the legs, which afflicts millions of patients with peripheral arterial disease.”

Speeding New Treatments

The NIH has tasked the University of Virginia researchers with evaluating the drug zibotentan, manufactured by AstraZeneca, to determine its effectiveness against peripheral arterial disease, or PAD. Dubbed “Discovering New Therapeutic Uses for Existing Molecules,” the pilot initiative is led by the National Center for Advancing Translational Sciences.

This is the first series of awards in the pilot program, which was established to identify new uses for molecules that already have gone through significant safety testing in humans for other indications. The goal is to speed the development of new treatments by harnessing the unknown potential of compounds that have gone through major steps in the development process.

“Innovative, collaborative approaches that improve the therapeutic pipeline are crucial for success,” said NIH director Dr. Francis S. Collins. “This unique collaboration between academia and industry holds the promise of trimming years from the long and expensive process of drug development.”

Other academic institutions receiving awards include Yale, the Mayo Clinic, Baylor College of Medicine and Virginia Commonwealth University. Details on the selected projects are available here.

In addition to AstraZeneca, industry participants in the pilot effort include AbbVie, Bristol-Myers Squibb Co., Eli Lilly and Co., GlaxoSmithKline, Janssen Pharmaceutical Research & Development LLC, Pfizer and Sanofi.

VN:F [1.9.22_1171]
Rating: 10.0/10 (1 vote cast)
VN:F [1.9.22_1171]
Rating: +1 (from 1 vote)
University of Virginia wins NIH backing for peripheral arterial disease research, 10.0 out of 10 based on 1 rating

About Universities News • Free Website Templates - Downlaod Full Themes